Hengrui Medicine (01276.HK) 2025 interim report: revenue and net profit hit a new high, strong performance growth.

According to the Securities Times app, on August 20th, Hengrui Medicine (stock code: 600276.SH; 01276.HK) released its 2025 interim report. The report shows that in the first half of 2025, the company achieved operating income of 15.761 billion yuan, a year-on-year increase of 15.88%; net profit attributable to shareholders of listed companies was 4.45 billion yuan, a year-on-year increase of 29.67%; and net cash flow from operating activities reached 4.3 billion yuan, a year-on-year increase of 41.80%. The company's revenue, net profit, and net cash flow from operating activities have all reached new highs compared to the same period in previous years, and performance has entered a period of explosive growth. The company continues to increase its innovation efforts, maintaining a high level of research and development investment. During the reporting period, the company's research and development investment was 3.871 billion yuan, with 3.228 billion yuan in expense-based research and development investment.